Efficacy and safety of XELOX combined with neoadjuvant radiotherapy versus neoadjuvant chemotherapy in locally advanced gastric cancer
The XELOX regimen combined with neoadjuvant chemoradiotherapy provided superior downstaging, short-term pathological response, and local control benifits compared to perioperative chemotherapy alone, with similar surgical safety profiles.
Authors
- Y.P. Liu (ORCID: https://orcid.org/0000-0002-4571-2226)
- Xiushen Wang (ORCID: https://orcid.org/0000-0002-3639-6719)
- Yue Cao (ORCID: https://orcid.org/0000-0003-3910-3261)
- Hang Xing (ORCID: https://orcid.org/0000-0003-3917-8343)
- Chuang Shang
- Ting Wang (ORCID: https://orcid.org/0000-0002-6800-242X)
- Siyi Wang (ORCID: https://orcid.org/0000-0002-3754-2861)
- Shanshan Bu (ORCID: https://orcid.org/0000-0002-9462-0491)
- Xiaoqun Dong
- Zhandong Zhang
- Xiance Tang
Institutions
- Nantong University (CN)
- Brown University (US)
- Rhode Island Hospital (US)
- Zhengzhou University (CN)
- Affiliated Hospital of Nantong University (CN)
- First Hospital of China Medical University (CN)
- Henan Cancer Hospital (CN)
- China Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1186/s12885-025-14103-1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00